Evommune, Inc. (EVMN) company profile
Close on Nov 13, 2026Market cap $276.91MP/E –Yield –
About Evommune
Pharmaceutical Preparations, SIC 2834
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing a portfolio of product candidates that target key drivers of chronic inflammation, with initial clinical development programs in chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline features EVO756, an oral small molecule antagonist targeting MRGPRX2 to modulate mast cells and peripheral sensory neurons, and EVO301, an engineered IL-18 binding protein fusion molecule. The company aims to address treatment gaps for patient populations suffering from chronic inflammatory conditions.
The company conducts clinical and operational activities in the United States, including multicenter clinical trials. Evommune's principal executive offices are located in Palo Alto, California, and the company also maintains leased office facilities in New York.
Summary of the business section of Evommune's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Evommune, Inc.
- Headquarters
- Palo Alto, CA
- Address
- 1891 Page Mill Rd
- Phone
- (650) 223-7745
- Website
- evommune.com
- Employees
- 48, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, New York, NY
Stock & identifiers
- Ticker
- EVMN
- Exchange
- NYSE
- IPO date
- Nov 6, 2025
- Shares outstanding
- 36M, Aug 4, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2044725
- CUSIP
- 30054Y107
- ISIN
- US30054Y1073
- FIGI
- BBG00Y79N887
- Share class FIGI
- BBG00Y79N8B3
- EIN
- 85-0742575
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Luis C. Pena | President & CEO, Director | 631,573 |
| Eugene Bauer | Chief Medical Officer, Director | 270,818 |
| Kyle Carver | Chief Financial Officer | 60,335 |
| Janice Suzann Drew | Chief of Dev. Operations | 71,633 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | 46,403 |
| Gregory S. Moss | Chief Business & Legal Officer | 64,010 |
| Arthur S. Kirsch | Director | 10,000 |
| Benjamin F. McGraw Iii | Director | – |
| David E. Cohen | Director | 17,609 |
| 7 Cooperative UA LSP | Director | 10,217,946 |
| Weegen Felice Isabel Verduyn-van | Director | 5,288,313 |
| Peter Kolchinsky | Director | – |
| Capital Healthcare Fund LP RA | Director | 2,710,293 |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Rajeev M. Shah | Director | – |
| Ra Capital Management, L.P. | Director | 784,345 |
| Robert Lorne Hopfner | Director | 3,372,001 |
| Pivotal bioVenture Partners Fund I, L.P. | Director | – |
| bioVenture Partners Fund I. U.G.P. Ltd Pivotal | Director | – |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Director | 294,502 |
| Derek DiRocco | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Luis Peña Chief Executive Officer | $588.46K | $740.68K | $9.69M | – | $11.02M | +48% |
| Gregory S. Moss Chief Business & Legal Officer | $515.04K | $508.43K | $3.57M | $6.90K | $4.60M | +239% |
| Kyle Carver Chief Financial Officer | $501.88K | $496.66K | $3.40M | $6.90K | $4.40M | +256% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 6, 2025
- Offer price
- $16.00
- Securities offered
- 9,375,000
- Gross proceeds
- $150.00M
- Exchange
- NYSE
- First trading day
- Nov 6, 2025
- First-day close
- $20.23+26.4%
- Lock-up ends (est.)
- May 5, 2026
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 6, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 4, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?